Life Sciences

  • November 10, 2026

    Pharma Co. Investors Ink $4M Deal In FDA Hurdle Suit

    Verrica Pharmaceuticals and a group of investors have reached a $4 million deal to end claims that the company hid obstacles it faced in obtaining U.S. Food and Drug Administration approval for its lead product.

  • November 10, 2026

    LA Cannabis Retailer Sued Over Email 'Spy Pixels'

    A Los Angeles dispensary placed "malicious" code in marketing emails that spied on a consumer, recorded when she opened the messages and her location, forwarding the information to data-broker vendors, according to a California state lawsuit which seeks $1,000 per email and $5,000 per privacy violation.

  • November 10, 2026

    Idaho Judge Stays Abortion Relief, Citing 9th Circ. Ruling

    An Idaho federal judge on Tuesday stayed his finding that the state would violate the 14th Amendment by criminalizing certain abortions performed by a doctor challenging the state's abortion laws, saying he is bound by a Ninth Circuit decision he "strongly disagrees" with.

  • November 10, 2026

    Drugmaker Inks $2.5M Deal In Failed Weight Loss Drug Suit

    Drugmaker Skye Bioscience Inc. has reached a $2.5 million settlement with investors that would end a proposed securities class action alleging the company overhyped a weight-loss drug, causing its stock price to plummet once the truth came to light.

  • November 10, 2026

    11th Circ. Asked To Nix Penalties For Captive Deductions

    The U.S. Tax Court improperly imposed additional accuracy-related penalties against a Florida business for deductions it took for microcaptive insurance expenses, the business' owner told the Eleventh Circuit, saying the Tax Court's analysis of the case can't be reconciled with binding circuit precedent.

  • November 10, 2026

    Stryker Shorted Wash. Workers On Breaks, Wages, Suit Says

    A medical device company failed to provide Washington hourly workers with required meal and rest breaks, underpaid their wages and restricted their ability to discuss their pay, according to a proposed class action removed to Washington federal court.

  • November 10, 2026

    Oura Buys Healthcare AI Platform In $625M Deal

    Health intelligence platform Oura, advised by Latham & Watkins LLP, on Tuesday unveiled plans to acquire artificial intelligence-native primary care company Counsel Health in a $625 million deal.

  • November 10, 2026

    Judge Again Declines Recusal Over Wife's Blank Rome Ties

    The Pennsylvania state judge overseeing Philadelphia's Zantac mass tort litigation has again rejected claims that he might have a conflict of interest because his wife's firm represents a defendant in one of more than 500 such cases, pointing out that the case in question has been resolved.

  • November 10, 2026

    Pharma Co. Invatech Can Stay In Chapter 11, For Now

    A New Jersey bankruptcy judge on Tuesday denied the Office of the U.S. Trustee's bid to convert Invatech's bankruptcy to a Chapter 7 as the former generic pharmaceutical group works to wrap up an administratively insolvent Chapter 11.

  • November 10, 2026

    Judge Will Reduce 'Shocking' $88M Mesh Bellwether Verdict

    A Massachusetts federal judge said Tuesday she will reduce an $88 million verdict awarded to an Alabama couple in the first bellwether hernia mesh trial against Medtronic subsidiary Covidien LP, saying the award appeared to be "the product of passion."

  • November 09, 2026

    Fed. Circ. Presses Medytox On Bid To Save ITC Theft Case

    A Federal Circuit judge on Monday appeared perplexed by medical aesthetics provider Medytox Inc.'s position that the U.S. International Trade Commission wrongly rejected its claim that a rival stole its anti-wrinkle technology, saying Medytox's argument "has nothing to do" with the ruling.

  • November 09, 2026

    9th Circ. Undoes Royalties Award In Anesthetic Contract Case

    The Ninth Circuit has set aside a judgment directing Research Development Foundation to pay royalties to Pacira Pharmaceuticals Inc. in a contract dispute involving the anesthetic Exparel, further remanding the case for a recalculation of prejudgment interest.

  • November 09, 2026

    Ohio AG Asks To Streamline Drug Pricing Suit

    The attorney general of Ohio is seeking to amend its complaint accusing Express Scripts and several related entities of conspiring to raise prescription drug prices.

  • November 09, 2026

    FDA Orders New GLP-1 Risk Warnings Over Vision Loss

    The U.S. Food and Drug Administration on Monday said it is requiring new warnings on GLP-1 medications, the group of blockbuster drugs prescribed for diabetes and weight loss, for a serious, rare condition that can cause sudden and possibly permanent vision loss in one eye.

  • November 09, 2026

    Compass Submits Psilocybin Depression Drug To FDA

    Pharmaceutical company Compass Pathways announced Monday that it had submitted to the U.S. Food and Drug Administration a new drug application to treat treatment-resistant depression with psilocybin, the primary compound in psychoactive mushrooms.

  • November 09, 2026

    Teva Defends Mifepristone Antitrust Case Against Corcept

    Teva Pharmaceuticals has told a California federal court there is plenty of evidence for a jury to find that Corcept Therapeutics blocked generic competition for its cortisol disorder treatment Korlym by using an exclusive distribution deal with a specialty pharmacy.

  • November 09, 2026

    National Science Foundation Sued Over Plan To Defund Unit

    Researchers on Monday challenged the impending phase-out of an office of the National Science Foundation that funds 64% of U.S. research in the social sciences, calling the move to eliminate funding illegal and devastating for their fields.

  • November 09, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week cleared the way for Cloudflare Inc. to seek immediate review of an injunction blocking a stock restructuring designed to preserve its founders' control, while setting a January hearing in a similar dispute over Meta Platforms Inc.'s plan to create nonvoting shares.

  • November 09, 2026

    Pharmacy Tech's COVID Vax Bias Suit Falls Short At 7th Circ.

    The Seventh Circuit refused to reopen a suit alleging an Illinois county hospital fired a pharmacy technician for requesting a religious exemption from the COVID-19 vaccine, saying it was bound by a recent ruling nixing a similar case.

  • November 09, 2026

    Justices Decline Review In Real Estate Row Over Pot Biz

    The U.S. Supreme Court on Monday declined to hear a real estate developer's case against the city of Pontiac, Michigan, alleging municipal officials violated constitutional rights by delaying approvals of a proposed cannabis operation until it was no longer viable.

  • November 09, 2026

    Justices Seek US View On Pharma's Iraq Terror Liability

    The U.S. Supreme Court on Monday invited the U.S. solicitor general to opine on a lawsuit accusing pharmaceutical companies of aiding a Hezbollah-linked militia's terrorist activities in Iraq, after the D.C. Circuit held the plaintiffs adequately alleged that the companies' participation was conscious and voluntary.

  • November 09, 2026

    Justices Pass On Reviewing MS Drug Arbitration Feud

    The U.S. Supreme Court on Monday passed on reviewing a Second Circuit decision that refused to add some $66 million to a $16.6 million arbitral award issued to Acorda Therapeutics in a multiple sclerosis drug dispute, rejecting a petition that sought clarity on when an arbitrator "manifestly disregards" the law.

  • November 09, 2026

    Justices Won't Review DOD, Subcontractor Software Feud

    The U.S. Supreme Court on Monday declined to review a dispute over rights to healthcare software for a U.S. Army veterinary records system, after the Federal Circuit held a defense subcontractor failed to present a valid contract claim.

  • November 06, 2026

    'Halfhearted' Conferral Not Enough In Mosquito-Patch Feud

    A Florida federal judge denied a bid by a German mosquito-bite patch maker to compel arbitration of a dispute over a license and distribution agreement for the products, ruling that the company's "halfhearted" conferral attempt with opposing counsel violated local rules.

  • November 06, 2026

    $45M Deal In IRhythm Heart Device Investor Suit Gets Final OK

    A California federal court granted final approval to a $45 million settlement resolving proposed class action allegations that digital healthcare company iRhythm Technologies inflated stock prices with misrepresentations about its heart-event monitoring device.

Expert Analysis

  • Planning Personal Phone Collections Before Discovery Begins

    Author Photo

    For counsel planning a personal phone collection as part of the litigation discovery process, it's important to take early steps to ensure that necessary information will be obtained without exposing unrelated information or running into access issues, says Jeremy Horowitz at MARA Forensics.

  • Calif. Sex Harassment Cases Clarify Limits On EFAA Waivers

    Author Photo

    Two recent rulings in California confirm that the plaintiff's knowledge drives waiver analysis under the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act, underscoring that employers should build a strong evidentiary record and pick their battles, says Ellen Connelly Cohen at Call & Jensen.

  • 2 Del. Rulings Show Postclosing Earnout Arrangement Risks

    Author Photo

    Two recent Delaware Court of Chancery decisions illustrate the contractual and fiduciary duty risks associated with earnout provisions in M&A transactions, offering lessons on allocating postclosing control, drafting enforceable earnout covenants and managing executives whose pay depends on the outcome, says Chris Brown at Taft.

  • Opinion

    Judges Must Turn To Merits Earlier To Fix Civil Justice System

    Author Photo

    The U.S. justice system is long overdue for a cultural shift that encourages judges to engage with the merits of a case from the outset, which would help to cut through procedural complexities and deliver high-quality justice efficiently and at lower cost, says Steven Kayman at Rottenberg Lipman.

  • How Analytical Advances Reshape Biologic Patent Strategy

    Author Photo

    As regulators shift away from relying on comparative clinical efficacy studies in biosimilar development, and more toward analytical data, practitioners should pay closer attention to post-translational modifications when evaluating patentability, says Gina Nellesen at Global Patent Group.

  • Series

    Open-Water Swimming Makes Me A Better Lawyer

    Author Photo

    Swimming long distances in open waters is not necessarily an escape from my intellectual property practice, but a complementary discipline that similarly rewards sustained attention, intellectual curiosity, resilience and the ability to pursue a distant objective without losing command of the immediate task, says Christina MacDougall at Morgan Lewis.

  • Opinion

    The Invisible AI Danger That May Undermine Legal Profession

    Author Photo

    A public database tracking cases involving hallucinations generated by artificial intelligence recently surpassed 2,200 entries, but the bigger risk underlying attorneys’ use of such tools is that they will slowly surrender their judgment to AI and lose analytical skills, says Massachusetts District Court Associate Justice Brian Palmucci.

  • How Cos. Using AI Agents Can Avoid Protected Data Incidents

    Author Photo

    For businesses whose deployed artificial intelligence agents could enter other companies' systems and steal protected data, deployers can take several steps before an incident to test the configured agent, such as limiting it to approved systems and destinations and requiring human escalation when tasks stall, says Steven Carlson at von Briesen & Roper.

  • FDA Classification Setback Bodes Well For Wound Care Cos.

    Author Photo

    A Georgia federal court's recent decision in MiMedx v. U.S. Food and Drug Administration constrains the FDA's analytical framework for classifying certain wound care products as biological products, carrying important ramifications for manufacturers seeking to avoid heightened regulatory requirements, say attorneys at Hyman Phelps.

  • Lessons For Cannabis Dispensaries From Web Tracking Suits

    Author Photo

    The trajectory of health-tracking litigation in Florida and elsewhere suggests that patient privacy claims will not disappear quickly, so dispensaries should audit their sites, tighten consent and align their disclosures with their actual practices, say attorneys at Buchanan Ingersoll.

  • How AI Could Help Judges Spot Their Own Biases

    Author Photo

    In close cases where there’s room for discretion, artificial intelligence could challenge judges’ implicit biases by running counterfactual tests at scale — but any judicial use of such tools would need guardrails, say Arnold Peter at Peter Law and Nancy Rapoport at University of Nevada.

  • 3 Eligibility Rulings Show Risks Of Broad Claim Constructions

    Author Photo

    Several recent decisions from the Federal Circuit, including its ruling in Berkeley v. W.W. Grainger, highlight the importance of identifying the inventive aspects of a patent early in the case so that patentees do not inadvertently read the inventive features out of their own claims, say attorneys at MoFo.

  • 3 Strategies To Reduce AI Sycophancy In Legal Work

    Author Photo

    The tendency of generative artificial intelligence models to tell users what they want to hear can reinforce attorneys’ confirmation bias when testing the strength of arguments, and it can’t simply be prompted away — but a few practices can help mitigate it, says Michael Ott at Ice Miller.

  • DOJ Directive Gives Contractors A Fraud Risk Road Map

    Author Photo

    For government contractors, the 10 factors described in the U.S. Department of Justice's recent corporate fraud enforcement directive function as a de facto scoring rubric for internal audits that mirrors what prosecutors will prioritize, say attorneys at Spencer Fane.

  • Why Inter Partes Reviews May Be On The Rebound

    Author Photo

    Recent inter partes review data shows that rates of referrals and institution rates at the U.S. Patent and Trademark Office are increasing, potentially indicating, among other reasons, that patent challengers are adjusting to the USPTO's policy changes, say attorneys at Sterne Kessler.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here